As the future of the immuno-oncology therapy concept is positioned in combination therapies, NR2F6 might be an emerging next-generation target that combines intracellular as well as surface receptor pathways, thus improving T cell efficacy and therapeutic outcomes, and increasing the percentage of cancer patients who positively respond to treatment. Here, NR2F6 is linked to cancer.